Effect of previous treatment and sputum quality on diagnostic accuracy of Xpert((R)) MTB/RIF

2017

Article référencé dans le Web of Science WOS:000397481900007

Acuna-Villaorduna C., Orikiriza R., Nyehangane D., White L. F., Mwanga-Arnumpaire J., Kim S., Bonnet Maryline, Fennelly K. P., Boum Y., Jones-Lopez E. C.

International Journal of Tuberculosis and Lung Disease, 2017, 21 (4), p. 389-397 ISSN 1027-3719

SETTING: In early studies, Xpert((R)) MTB/RIF accurately detected culture-proven pulmonary tuberculosis (TB). Recent reports have, however, found a lower than expected specificity in previously treated TB patients. OBJECTIVE: To investigate the diagnostic accuracy of Xpert in presumptive pulmonary TB patients in Southwestern Uganda. DESIGN: We obtained demographic and clinical information and collected three sputum samples from each patient for smear microscopy, Xpert and culture. We estimated Xpert sensitivity and specificity against culture, and stratified the analysis by previous treatment and sputum quality status. RESULTS: We analyzed results from 860 presumptive TB patients, including 109 (13%) with a previous history of anti-tuberculosis treatment; 205 (24%) were culture-positive. Xpert specificity was lower (91.8%, 95%CI 84.9-96.2) in previously treated than in new TB patients (97.5%, 95%CI 96.1-98.5; P = 0. 0 1). In an adjusted analysis, patients with culture-,Xpert+results were more likely to have been previously treated for TB (OR 8.3, 95%CI 2.1-32.0; P = 0.002), and to have mucosalivary sputum (OR 4.1, 95%CI 1.1-14.6; P = 0.03), but were less likely to self-report fever (OR 0.23, 95%CI 0.1-0.7; P = 0.008) than patients with concordant positive results. CONCLUSION: Xpert specificity was lower in previously treated patients with suspected TB. The clinical and programmatic impact of culture-, Xpert+results requires evaluation in future studies.

Santé : généralités [050] ; Biotechnologies [084]

Fonds IRD [F B010081586]

PAR00016038